Literature DB >> 12522687

Interaction between the LDL-receptor gene bearing a novel mutation and a variant in the apolipoprotein A-II promoter: molecular study in a 1135-member familial hypercholesterolemia kindred.

Daisuke Takada1, Mitsuru Emi, Yoichi Ezura, Yukiko Nobe, Katsumi Kawamura, Yasuhiko Iino, Yasuo Katayama, Yuanpei Xin, Lily L Wu, Stacey Larringa-Shum, Susan H Stephenson, Steven C Hunt, Paul N Hopkins.   

Abstract

Lipid and lipoprotein concentrations in plasma generally reflect complex influences of multiple genetic loci. Even an autosomal dominant disorder, familial hypercholesterolemia (FH), is characterized by phenotypic heterogeneity, as low-density lipoprotein (LDL) levels vary widely within the same pedigree. Molecular screening for LDL receptor ( LDLR) mutations among 75 patients with clinically apparent FH led to identification of a novel splice-site mutation (IVS14+1 G>A) shared by 14 patients. Genealogical research confirmed that all 14 carriers were part of the same 1135-member pedigree with a common ancestor. The mutation resulted in an abruptly truncated LDLR protein, reducing functional LDLR activity by half in heterozygous carriers of the mutant allele. Of the 208 members of the kindred who were screened for the presence of this LDLR mutation, we identified 94 carriers and 114 noncarriers. Nine principal apolipoprotein genes that might affect LDL cholesterol differentially according to LDL-receptor status were examined in this pedigree. Strikingly lower total cholesterol and LDL-cholesterol values were observed among the majority of the LDLR mutation carriers who were simultaneously homozygous for the -265C variant of apoA-II (total cholesterol: 324 +/- 8 vs 244 +/- 19 mg/dl, P = 0.0015; LDL-cholesterol: 237 +/- 8 vs 155 +/- 18 mg/dl, P = 0.0008). In vitro transfection assays showed that transcriptional activity of the apoA-II promoter was reduced by 30% in the -265C variant as compared with the -265T variant. We thus concluded that one variant of the apoA-II gene was associated with reduced plasma LDL cholesterol only in FH patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12522687     DOI: 10.1007/s100380200101

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  17 in total

Review 1.  Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease.

Authors:  George Yuan; Jian Wang; Robert A Hegele
Journal:  CMAJ       Date:  2006-04-11       Impact factor: 8.262

2.  Genomic susceptibility Loci for brain atrophy, ventricular volume, and leukoaraiosis in hypertensive sibships.

Authors:  Stephen T Turner; Myriam Fornage; Clifford R Jack; Thomas H Mosley; David S Knopman; Sharon L R Kardia; Eric Boerwinkle; Mariza de Andrade
Journal:  Arch Neurol       Date:  2009-07

3.  APOA2, dietary fat, and body mass index: replication of a gene-diet interaction in 3 independent populations.

Authors:  Dolores Corella; Gina Peloso; Donna K Arnett; Serkalem Demissie; L Adrienne Cupples; Katherine Tucker; Chao-Qiang Lai; Laurence D Parnell; Oscar Coltell; Yu-Chi Lee; Jose M Ordovas
Journal:  Arch Intern Med       Date:  2009-11-09

4.  Hypercholesterolemia associated with splice-junction variation of inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) gene.

Authors:  Yuko Fujita; Yoichi Ezura; Mitsuru Emi; Keiko Sato; Daisuke Takada; Yasuhiko Iino; Yasuo Katayama; Kaneo Takahashi; Kouhei Kamimura; Hideaki Bujo; Yasushi Saito
Journal:  J Hum Genet       Date:  2003-12-06       Impact factor: 3.172

5.  Soluble epoxide hydrolase variant (Glu287Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: intrafamilial association study in an eight-generation hyperlipidemic kindred.

Authors:  Keiko Sato; Mitsuru Emi; Yoichi Ezura; Yuko Fujita; Daisuke Takada; Tomoaki Ishigami; Satoshi Umemura; Yunpei Xin; Lily L Wu; Stacey Larrinaga-Shum; Susan H Stephenson; Steven C Hunt; Paul N Hopkins
Journal:  J Hum Genet       Date:  2003-12-13       Impact factor: 3.172

6.  Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (Lp-PLA2) deficiency patients.

Authors:  Mitsuaki Ishihara; Tadao Iwasaki; Makoto Nagano; Jun Ishii; Mayumi Takano; Takeshi Kujiraoka; Masahiro Tsuji; Hiroaki Hattori; Mitsuru Emi
Journal:  J Hum Genet       Date:  2004-05-18       Impact factor: 3.172

7.  Hypertriglyceridemia associated with amino acid variation Asn985Tyr of the RP1 gene.

Authors:  Yuko Fujita; Yoichi Ezura; Mitsuru Emi; Shuji Ono; Daisuke Takada; Kaneo Takahashi; Kouhei Uemura; Yasuhiko Iino; Yasuo Katayama; Hideaki Bujo; Yasushi Saito
Journal:  J Hum Genet       Date:  2003-05-23       Impact factor: 3.172

8.  A promoter SNP (-1323T>C) in G-substrate gene (GSBS) correlates with hypercholesterolemia.

Authors:  Shuji Ono; Yoichi Ezura; Mitsuru Emi; Yuko Fujita; Daisuke Takada; Keiko Sato; Tomoaki Ishigami; Satoshi Umemura; Kaneo Takahashi; Kouhei Kamimura; Hideaki Bujo; Yasushi Saito
Journal:  J Hum Genet       Date:  2003-09-03       Impact factor: 3.172

9.  Association between the APOA2 promoter polymorphism and body weight in Mediterranean and Asian populations: replication of a gene-saturated fat interaction.

Authors:  D Corella; E S Tai; J V Sorlí; S K Chew; O Coltell; M Sotos-Prieto; A García-Rios; R Estruch; J M Ordovas
Journal:  Int J Obes (Lond)       Date:  2010-10-26       Impact factor: 5.095

10.  Studies of gene variants related to inflammation, oxidative stress, dyslipidemia, and obesity: implications for a nutrigenetic approach.

Authors:  Maira Ladeia R Curti; Patrícia Jacob; Maria Carolina Borges; Marcelo Macedo Rogero; Sandra Roberta G Ferreira
Journal:  J Obes       Date:  2011-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.